The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | 5-year follow-up of CheckMate 649 in advanced GC/GEJC/EAC
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the 5-year follow-up results from the CheckMate 649 trial (NCT02872116) of first-line nivolumab plus chemotherapy versus chemotherapy alone for advanced non-HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma. Nivolumab-based therapy sustained improvements in overall and progression-free survival across all PD-L1 subgroups and randomized patients. The regimen also demonstrated higher and more durable response rates without new safety concerns. These findings reinforce nivolumab plus chemotherapy as a standard first-line option in this setting. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
